Search

Your search keyword '"Carlisle, Jennifer"' showing total 144 results
Start Over Author "Carlisle, Jennifer"
144 results on '"Carlisle, Jennifer"'

1. BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer

Author

Valanparambil, Rajesh M., Lai, Lilin, Johns, Margaret A., Davis-Gardner, Meredith, Linderman, Susanne L., McPherson, Tarrant Oliver, Chang, Andres, Akhtar, Akil, Gamarra, Estefany L. Bocangel, Matia, Hayley, McCook-Veal, Ashley A., Switchenko, Jeffrey, Nasti, Tahseen H., Green, Felicia, Saini, Manpreet, Wieland, Andreas, Pinsky, Benjamin A., Solis, Daniel, Dhodapkar, Madhav V., Carlisle, Jennifer, Ramalingam, Suresh, Ahmed, Rafi, and Suthar, Mehul S.

Published
2023
Full Text
View/download PDF

2. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.

Author

Ramalingam, Suresh S and Carlisle, Jennifer W

Abstract

Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer. Infographic [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis

Author

Patel, Jimmy S, primary, Woo, Yena, additional, Draper, Amber, additional, Jansen, Caroline S, additional, Carlisle, Jennifer W, additional, Innominato, Pasquale F, additional, Lévi, Francis A, additional, Dhabaan, Layla, additional, Master, Viraj A, additional, Bilen, Mehmet A, additional, Khan, Mohammad K, additional, Lowe, Michael C, additional, Kissick, Haydn, additional, Buchwald, Zachary S, additional, and Qian, David C, additional

Published
2024
Full Text
View/download PDF

7. 742 Phase 1/2 study of the bispecific 4–1BB and PD-L1 antibody INBRX-105 alone and in combination with pembrolizumab in select solid tumors

Author

Park, Jong Chul, primary, Berz, David, additional, Sharma, Manish, additional, Massarelli, Erminia, additional, Hauke, Ralph J, additional, Tsai, Frank Yung-Chin, additional, Hong, David, additional, Akhave, Neal, additional, Call, Justin A, additional, Carlisle, Jennifer, additional, Sanborn, Rachel E, additional, Haas, Naomi B, additional, Hamm, John, additional, Ross Camidge, D, additional, Spira, Alexander I, additional, Andrianov, Vasily, additional, O’Neill, Brianne, additional, Kinkead, Heather, additional, and Tolcher, Anthony W, additional

Published
2023
Full Text
View/download PDF

8. Characteristics and anatomic location of PD-1 + TCF1 + stem-like CD8 T cells in chronic viral infection and cancer

Author

Im, Se Jin, primary, Obeng, Rebecca C., additional, Nasti, Tahseen H., additional, McManus, Daniel, additional, Kamphorst, Alice O., additional, Gunisetty, Sivaram, additional, Prokhnevska, Nataliya, additional, Carlisle, Jennifer W., additional, Yu, Ke, additional, Sica, Gabriel L., additional, Cardozo, Lucas E., additional, Gonçalves, André N. A., additional, Kissick, Haydn T., additional, Nakaya, Helder I., additional, Ramalingam, Suresh S., additional, and Ahmed, Rafi, additional

Published
2023
Full Text
View/download PDF

9. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells

Author

Jansen, Caroline S., Prokhnevska, Nataliya, Master, Viraj A., Sanda, Martin G., Carlisle, Jennifer W., Bilen, Mehmet Asim, Cardenas, Maria, Wilkinson, Lake, Ross, Sowalsky, Adam G., Valanparambil, Rajesh M., Hudson, William H., McGuire, Donald, Melnick, Kevin, Khan, Amir I., Kim, Kyu, Chang, Yu Min, Kim, Alice, Filson, Christopher P., Alemozaffar, Mehrdad, Osunkoya, Adeboye O., Mullane, Patrick, Ellis, Carla, Akondy, Rama, Im, Se Jin, Kamphorst, Alice O., Reyes, Adriana, Liu, Yuan, and Kissick, Haydn

Subjects
Oncology, Experimental, CD8 lymphocytes -- Physiological aspects -- Health aspects, Tumors -- Physiological aspects -- Development and progression, Cell differentiation -- Research, Cancer -- Research, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Tumour-infiltrating lymphocytes are associated with a survival benefit in several tumour types and with the response to immunotherapy.sup.1-8. However, the reason some tumours have high CD8 T cell infiltration while others do not remains unclear. Here we investigate the requirements for maintaining a CD8 T cell response against human cancer. We find that CD8 T cells within tumours consist of distinct populations of terminally differentiated and stem-like cells. On proliferation, stem-like CD8 T cells give rise to more terminally differentiated, effector-molecule-expressing daughter cells. For many T cells to infiltrate the tumour, it is critical that this effector differentiation process occur. In addition, we show that these stem-like T cells reside in dense antigen-presenting-cell niches within the tumour, and that tumours that fail to form these structures are not extensively infiltrated by T cells. Patients with progressive disease lack these immune niches, suggesting that niche breakdown may be a key mechanism of immune escape. The authors examine the immune cell infiltrates of human tumours and provide evidence for a population of CD8 T cells with stem-cell characteristics and proliferative capacity that reside in an antigen-presenting niche within tumours., Author(s): Caroline S. Jansen [sup.1] , Nataliya Prokhnevska [sup.1] , Viraj A. Master [sup.1] [sup.2] , Martin G. Sanda [sup.1] [sup.2] , Jennifer W. Carlisle [sup.2] [sup.3] , Mehmet Asim [...]

Published
2019
Full Text
View/download PDF

11. Spectacular Progress in Lung Cancer Care: 'What we're doing is actually making an impact.'

Author

Carlisle, Jennifer W.

Subjects
Ipilimumab, Cancer patients, Lung cancer, Non-small cell -- Genetic aspects, Drug approval, Vaccines, Health
Abstract

The coronavirus disease 2019 (COVID-19) pandemic stole the medical spotlight in 2020, and rightfully so. But what was sometimes lost in the never-ending news cycle and the coverage of the [...]

Published
2021

12. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Author

Chaft, Jamie E., Oezkan, Filiz, Kris, Mark G., Bunn, Paul A., Wistuba, Ignacio I., Kwiatkowski, David J., Owen, Dwight H., Tang, Yan, Johnson, Bruce E., Lee, Jay M., Lozanski, Gerard, Pietrzak, Maciej, Seweryn, Michal, Byun, Woo Yul, Schulze, Katja, Nicholas, Alan, Johnson, Ann, Grindheim, Jessica, Hilz, Stephanie, Shames, David S., Rivard, Chris, Toloza, Eric, Haura, Eric B., McNamee, Ciaran J., Patterson, G. Alexander, Waqar, Saiama N., Rusch, Valerie W., Carbone, David P., Shum, Elaine, Nagasaka, Misako, Koczywas, Marianna, Garon, Edward B., Finley, David J., Camidge, David R., Carlisle, Jennifer W., and Blasberg, Justin D.

Subjects
Medizin, General Medicine, General Biochemistry, Genetics and Molecular Biology
Abstract

In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; ≤10% viable malignant cells) in resected tumors withoutEGFRorALKalterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14–28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging. The most common adverse events during the neoadjuvant phase were fatigue (39%, 71 of 181) and procedural pain (29%, 53 of 181), along with expected immune-related toxicities; there were no unexpected safety signals. In exploratory analyses, MPR was predicted using the pre-treatment peripheral blood immunophenotype based on 14 immune cell subsets. Immune cell subsets predictive of MPR in the peripheral blood were also identified in the tumor microenvironment and were associated with MPR. This study of neoadjuvant atezolizumab in a large cohort of patients with resectable non-small cell lung cancer was safe and met its primary end point of MPR ≥ 15%. Data from this single-arm, non-randomized trial suggest that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but additional studies are needed to determine whether these profiles can inform patient selection and new therapeutic approaches.

Published
2022
Full Text
View/download PDF

13. Shifting Sociodemographic Characteristics of a Phase I Clinical Trial Population at an NCI-Designated Comprehensive Cancer Center in the Southeast.

Author

Lalonde, Chloe S, Switchenko, Jeffrey M, Behera, Madhusmita, Bilen, Mehmet A, Owonikoko, Taofeek K, Kaufman, Jonathan L, Nooka, Ajay K, Lewis, Colleen M, Hitron, Elise, Collins, Hannah, Judson, Emma C, Alese, Olatunji B, Donald Harvey, R, and Carlisle, Jennifer W

Subjects
HUMAN research subjects, CLINICAL trials, SPECIALTY hospitals, CANCER treatment, DESCRIPTIVE statistics, RESEARCH funding, SOCIODEMOGRAPHIC factors, DEMOGRAPHIC characteristics
Abstract

Racial and ethnic minority populations are consistently under-represented in oncology clinical trials despite comprising a disproportionate share of a cancer burden. Phase I oncology clinical trials pose a unique challenge and opportunity for minority inclusion. Here we compared the sociodemographic characteristics of patients participating in phase 1 clinical trials a National Cancer Institute (NCI)-designated comprehensive center to all patients at the center, patients with new cancer diagnosis in metropolitan Atlanta and patients with new cancer diagnoses in the state of Georgia. From 2015 to 2020, 2325 patients (43.4% female, 56.6% male) consented to participate in a phase I trial. Grouped self-reported race distribution was 70.3% White, 26.2% Black, and 3.5% other. Of new patient registrations at Winship Cancer Institute (N = 107 497) (50% F, 50% M), grouped race distribution was 63.3% White, 32.0% Black, and 4.7% other. Patients with new cancer diagnoses in metro Atlanta from 2015 to 2016 (N = 31101) were 58.4% White, 37.2% Black, and 4.3% other. Race and sex distribution of phase I patients was significantly different than Winship patients (P <.001). Over time, percent of White patients decreased in both phase I and Winship groups (P =.009 and P <.001, respectively); percentage of females did not change in either group (P =.54 phase I, P =.063 Winship). Although phase I patients were more likely to be White, male, and privately ensured than the Winship cohort, from 2015 to 2020 the percentage of White patients in phase I trials and among all new patients treated at Winship decreased. The intent of characterizing existing disparities is to improve the representation of patients from racial and ethnic minority backgrounds in phase I clinical trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

14. Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non–small cell lung cancer.

Author

McCall, Neal S., Janopaul‐Naylor, James R., McGinnis, H. Scott, Kesarwala, Aparna H., Tian, Sibo, Stokes, William A., Shelton, Joseph W., Steuer, Conor E., Carlisle, Jennifer W., Leal, Ticiana A., Ramalingam, Suresh S., Bradley, Jeffrey D., and Higgins, Kristin A.

Subjects
NON-small-cell lung carcinoma, BLACK people, CHEMORADIOTHERAPY
Abstract

Background: The PACIFIC trial established consolidative durvalumab after concurrent chemoradiation as standard‐of‐care in patients with stage III or unresectable non–small cell lung cancer (NSCLC). Black patients, however, comprised just 2% (n = 14) of randomized patients in this trial, warranting real‐world evaluation of the PACIFIC regimen in these patients. Methods: This single‐institution, multi‐site study included 105 patients with unresectable stage II/III NSCLC treated with concurrent chemoradiation followed by durvalumab between 2017 and 2021. Overall survival (OS), progression‐free survival (PFS), and grade ≥3 pneumonitis‐free survival (PNFS) were compared between Black and non‐Black patients using Kaplan–Meier and Cox regression analyses. Results: A total of 105 patients with a median follow‐up of 22.8 months (interquartile range, 11.3–37.3 months) were identified for analysis, including 57 Black (54.3%) and 48 (45.7%) non‐Black patients. The mean radiation prescription dose was higher among Black patients (61.5 ± 2.9 Gy vs. 60.5 ± 1.9 Gy; p =.031), but other treatment characteristics were balanced between groups. The median OS (not‐reached vs. 39.7 months; p =.379) and PFS (31.6 months vs. 19.3 months; p =.332) were not statistically different between groups. Eight (14.0%) Black patients discontinued durvalumab due to toxicity compared to 13 (27.1%) non‐Black patients (p =.096). The grade ≥3 pneumonitis rate was similar between Black and non‐Black patients (12.3% vs. 12.5%; p =.973), and there was no significant difference in time to grade ≥3 PNFS (p =.904). Three (5.3%) Black patients and one (2.1%) non‐Black patient developed grade 5 pneumonitis. Conclusions: The efficacy and tolerability of consolidative durvalumab after chemoradiation appears to be comparable between Black and non‐Black patients. Consolidative durvalumab after concurrent chemoradiation has similar efficacy and tolerability between Black and non‐Black patients with unresectable stage II/III non–small cell lung cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer.

Author

Se Jin Im, Obeng, Rebecca C., Nasti, Tahseen H., McManus, Daniel, Kamphorst, Alice O., Gunisetty, Sivaram, Prokhnevska, Nataliya, Carlisle, Jennifer W., Ke Yu, Sica, Gabriel L., Cardozo, Lucas E., Gonçalves, André N. A., Kissick, Haydn T., Nakaya, Helder I., Ramalingam, Suresh S., and Ahmed, Rafi

Subjects
T cells, CD8 antigen, VIRUS diseases, LYMPHOCYTIC choriomeningitis virus, TUMOR-infiltrating immune cells
Abstract

CD8 T cells play an essential role in antitumor immunity and chronic viral infections. Recent findings have delineated the differentiation pathway of CD8 T cells in accordance with the progenitor-progeny relationship of TCF1+ stem-like and Tim-3+ TCF1− more differentiated T cells. Here, we investigated the characteristics of stem-like and differentiated CD8 T cells isolated from several murine tumor models and human lung cancer samples in terms of phenotypic and transcriptional features as well as their location compared to virus-specific CD8 T cells in the chronically lymphocytic choriomeningitis virus (LCMV)-infected mice. We found that CD8 tumor-infiltrating lymphocytes (TILs) in both murine and human tumors exhibited overall similar phenotypic and transcriptional characteristics compared to corresponding subsets in the spleen of chronically infected mice. Moreover, stem-like CD8 TILs exclusively responded and produced effector-like progeny CD8 T cells in vivo after antigenic restimulation, confirming their lineage relationship and the proliferative potential of stem-like CD8 TILs. Most importantly, similar to the preferential localization of PD-1+ stem-like CD8 T cells in T cell zones of the spleen during chronic LCMV infection, we found that the PD-1+ stem-like CD8 TILs in lung cancer samples are preferentially located not in the tumor parenchyma but in tertiary lymphoid structures (TLSs). The stem-like CD8 T cells are present in TLSs located within and at the periphery of the tumor, as well as in TLSs closely adjacent to the tumor parenchyma. These findings suggest that TLSs provide a protective niche to support the quiescence and maintenance of stem-like CD8 T cells in the tumor. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Abstract B085: Shifting sociodemographic characteristics of a phase 1 oncology clinical trial population at an NCI-designated Comprehensive Cancer Center in the Southeast in comparison to its catchment area

Author

Lalonde, Chloe S., primary, Switchenko, Jeffrey M., additional, Behera, Madhusmita, additional, Bilen, Mehmet A., additional, Owonikoko, Taofeek K., additional, Lewis, Colleen M., additional, Hitron, Elise, additional, Collins, Hannah, additional, Goodale, Tracy B., additional, Judson, Emma C., additional, Cavalcante, Ludimila, additional, Harvey, R. Donald, additional, and Carlisle, Jennifer W., additional

Published
2023
Full Text
View/download PDF

18. Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant

Author

Valanparambil, Rajesh M., primary, Carlisle, Jennifer, additional, Linderman, Susanne L., additional, Akthar, Akil, additional, Millett, Ralph Linwood, additional, Lai, Lilin, additional, Chang, Andres, additional, McCook-Veal, Ashley A., additional, Switchenko, Jeffrey, additional, Nasti, Tahseen H., additional, Saini, Manpreet, additional, Wieland, Andreas, additional, Manning, Kelly E., additional, Ellis, Madison, additional, Moore, Kathryn M., additional, Foster, Stephanie L., additional, Floyd, Katharine, additional, Davis-Gardner, Meredith E., additional, Edara, Venkata-Viswanadh, additional, Patel, Mit, additional, Steur, Conor, additional, Nooka, Ajay K., additional, Green, Felicia, additional, Johns, Margaret A., additional, O'Brein, Fiona, additional, Shanmugasundaram, Uma, additional, Zarnitsyna, Veronika I., additional, Ahmed, Hasan, additional, Nyhoff, Lindsay E., additional, Mantus, Grace, additional, Garett, Michael, additional, Edupuganti, Srilatha, additional, Behra, Madhusmita, additional, Antia, Rustom, additional, Wrammert, Jens, additional, Suthar, Mehul S., additional, Dhodapkar, Madhav V., additional, Ramalingam, Suresh, additional, and Ahmed, Rafi, additional

Published
2022
Full Text
View/download PDF

19. A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non–Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

Author

Osta, Badi El, primary, Carlisle, Jennifer, additional, Steuer, Conor, additional, Pakkala, Suchita, additional, Leal, Ticiana, additional, Dhodapkar, Madhav, additional, Liu, Yuan, additional, Chen, Zhengjia, additional, Owonikoko, Taofeek, additional, and Ramalingam, Suresh, additional

Published
2022
Full Text
View/download PDF

21. Impact of radiation dose to the immune cells in unresectable or stage III non-small cell lung cancer in the durvalumab era

Author

McCall, Neal S., primary, McGinnis, Hamilton S., additional, Janopaul-Naylor, James R., additional, Kesarwala, Aparna H., additional, Tian, Sibo, additional, Stokes, William A., additional, Shelton, Joseph W., additional, Steuer, Conor E., additional, Carlisle, Jennifer W., additional, Leal, Ticiana, additional, Ramalingam, Suresh S., additional, Bradley, Jeffrey D., additional, and Higgins, Kristin A., additional

Published
2022
Full Text
View/download PDF

22. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

Author

Carlisle, Jennifer Wilkinson, primary, Jansen, Caroline S, additional, Cardenas, Maria Andrea, additional, Sobierajska, Ewelina, additional, Reyes, Adriana Moon, additional, Greenwald, Rachel, additional, Del Balzo, Luke, additional, Prokhnevska, Nataliya, additional, Kucuk, Omer, additional, Carthon, Bradley C, additional, Mullane, Patrick Connor, additional, Osunkoya, Adeboye, additional, Baumgarten, Deborah, additional, Hosseinzadeh, Fares, additional, Wilkinson, Scott, additional, Lake, Ross, additional, Sowalsky, Adam G, additional, Liu, Yuan, additional, Master, Viraj A, additional, Bilen, Mehmet A, additional, and Kissick, Haydn, additional

Published
2022
Full Text
View/download PDF

23. Comparison of sociodemographic characteristics of a phase 1 clinical trial population at an NCI-designated comprehensive cancer center in the Southeast to catchment area.

Author

Lalonde, Chloe S., primary, Switchenko, Jeffrey M., additional, Behera, Madhusmita, additional, Bilen, Mehmet Asim, additional, Owonikoko, Taofeek K., additional, Lewis, Colleen Margaret, additional, Hitron, Elise, additional, Collins, Hannah, additional, Goodale, Tracy, additional, Judson, Emma C, additional, Harvey, R. Donald, additional, and Carlisle, Jennifer W, additional

Published
2022
Full Text
View/download PDF

24. High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

Author

Piper-Vallillo, A.J., primary, Rotow, Julia K., additional, Aredo, Jacqueline V., additional, Shaverdashvili, Khvaramze, additional, Luo, Jia, additional, Carlisle, Jennifer W., additional, Husain, Hatim, additional, Muzikansky, Alona, additional, Heist, Rebecca S., additional, Rangachari, Deepa, additional, Ramalingam, Suresh S., additional, Wakelee, Heather A., additional, Yu, Helena A., additional, Sequist, Lecia V., additional, Bauml, Joshua M., additional, Neal, Joel W., additional, and Piotrowska, Zofia, additional

Published
2022
Full Text
View/download PDF

25. First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).

Author

Qin, Angel, primary, Kalemkerian, Gregory Peter, additional, Mohindra, Nisha Anjali, additional, Patel, Jyoti D., additional, Karapetis, Christos Stelios, additional, Carlisle, Jennifer W, additional, Sands, Jacob, additional, Spira, Alexander I., additional, Gao, Bo, additional, Amin, Harshad, additional, Paudyal, Bishnuhari, additional, Frank, Genevieve, additional, Sun, Xuemei, additional, Xu, Yang, additional, Wang, Cunlin, additional, Fu, Tommy, additional, Winkler, Robert, additional, Liang, Zhiyan, additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2022
Full Text
View/download PDF

26. Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern

Author

Valanparambil, Rajesh M, primary, Carlisle, Jennifer, additional, Linderman, Susanne L., additional, Akthar, Akil, additional, Millett, Ralph Linwood, additional, Lai, Lilin, additional, Chang, Andres, additional, McCook, Ashley A., additional, Switchenko, Jeffrey, additional, Nasti, Tahseen H., additional, Saini, Manpreet, additional, Wieland, Andreas, additional, Manning, Kelly E., additional, Ellis, Madison, additional, Moore, Kathryn M., additional, Foster, Stephanie L., additional, Floyd, Katharine, additional, Davis-Gardner, Meredith E., additional, Edara, Venkata-Viswanadh, additional, Patel, Mit, additional, Steur, Conor, additional, Nooka, Ajay K., additional, Green, Felicia, additional, Johns, Margaret A., additional, O’Brein, Fiona, additional, Shanmugasundaram, Uma, additional, Zarnitsyna, Veronika I, additional, Ahmed, Hasan, additional, Nyhoff, Lindsay E., additional, Mantus, Grace, additional, Garett, Michael, additional, Edupuganti, Srilatha, additional, Behra, Madhusmita, additional, Antia, Rustom, additional, Wrammert, Jens, additional, Suthar, Mehul S., additional, Dhodapkar, Madhav V., additional, Ramalingam, Suresh, additional, and Ahmed, Rafi, additional

Published
2022
Full Text
View/download PDF

27. 929 Dissecting intratumoral immune organization: defining the comparative cellular composition of tertiary lymphoid structures T-cell supportive antigen presenting niches in renal tumors

Author

Jansen, Caroline, primary, Sobierajska, Ewelina, additional, Greenwald, Rachel, additional, Carlisle, Jennifer, additional, Mullane, Patrick, additional, Prokhnevska, Nataliya, additional, Cardenas, Maria, additional, Bilen, Mehmet, additional, Osunkoya, Adeboye, additional, Master, Viraj, additional, and Kissick, Haydn, additional

Published
2021
Full Text
View/download PDF

29. Pharmacological rescue of tumor intrinsic STING expression and immune response in LKB1-mutant lung cancer via the IAP-JAK regulatory axis

Author

Shu, Changfa, primary, Jin, Rui, additional, Niu, Qiankun, additional, Cicka, Danielle, additional, Doyle, Sean, additional, Wahafu, Alafate, additional, Fan, Dacheng, additional, Zheng, Xi, additional, Du, Yuhong, additional, Ivanov, Andrey A., additional, Doxie, Deon B, additional, Dhodapkar, Kavita M, additional, Carlisle, Jennifer, additional, Owonikoko, Taofeek, additional, Ramalingam, Suresh, additional, Sica, Gabriel, additional, Dhodapkar, Madhav V, additional, Zhou, Wei, additional, Mo, Xiulei, additional, and Fu, Haian, additional

Published
2021
Full Text
View/download PDF

30. Clinical and immunological response to checkpoint therapy in renal cell carcinoma is associated with TCF1+ CD8 T-cells in the tumor

Author

Carlisle, Jennifer, primary, Jansen, Caroline, additional, Cardenas, Maria, additional, Soierajska, Ewelina, additional, Moon, Adriana Reyes, additional, Greenwald, Rachel, additional, delBalzo, Luke, additional, Prokhnevska, Nataliya, additional, Kucuk, Omer, additional, Carthon, Bradley, additional, Mullane, Patrick, additional, Osunkoya, Adeboye, additional, Baumgarten, Deborah, additional, Hosseinzadeh, Fares, additional, Wilkinson, Scott, additional, Lake, Ross, additional, Sowalsky, Adam, additional, Liu, Yuan, additional, Master, Viraj, additional, Bilen, Mehmet, additional, and Kissick, Haydn, additional

Published
2021
Full Text
View/download PDF

31. PP01.55 Patient-reported experience as a baseline for 4R care sequence implementation at 9 cancer centers

Author

Weinberg, Frank, Weldon, Christine, Liu, Raymond, Velotta, Jeffrey, Katzel, Jed, Mohindra, Nisha, Feldman, Lawrence, Pasquinelli, Mary, Nguyen, Ryan, Prescott, Kevin, Chan, Cindy, Sakoda, Lori, Feliciano, Josephine, Sacks, Ruth, Carlisle, Jennifer, Mishra, Pooja, Morris, Angela, Waugh, Wendi, Martin, Jeremiah, Woodyard, Jenny, Khosla, Pam, Khan, Sarah, Paduri, Swetha, Ravelo, Arliene, Lycan, Thomas, Martin, Nikki, Boehmer, Leigh, Lile, Ashley, Sorgi, Marin, and Trosman, Julia

Published
2024
Full Text
View/download PDF

32. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Author

Sands, Jacob M, primary, Mandrekar, Sumithra J, additional, Kozono, David, additional, Oxnard, Geoffrey R, additional, Hillman, Shauna L, additional, Wigle, Dennis A, additional, Govindan, Ramaswamy, additional, Carlisle, Jennifer, additional, Gray, Jhanelle, additional, Salama, Joseph K, additional, Raez, Luis, additional, Ganti, Apar, additional, Foster, Nathan, additional, Malik, Shakun, additional, Bradley, Jeffrey, additional, Kelly, Karen, additional, Ramalingam, Suresh S, additional, and Stinchcombe, Thomas E, additional

Published
2021
Full Text
View/download PDF

35. Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

Author

Wong, Selina K., primary, Whisenant, Jennifer G., additional, Bestvina, Christine M., additional, Berry, Lynne D, additional, Owonikoko, Taofeek K., additional, Sanborn, Rachel E., additional, Lammers, Philip Edward, additional, El Osta, Badi Edmond, additional, Ramalingam, Suresh S., additional, Carlisle, Jennifer W, additional, Steuer, Conor Ernst, additional, Borghaei, Hossein, additional, Selvaggi, Giovanni, additional, Shyr, Yu, additional, Wakelee, Heather A., additional, Horn, Leora, additional, and Beckermann, Katy, additional

Published
2021
Full Text
View/download PDF

36. Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).

Author

Qin, Angel, primary, Kalemkerian, Gregory Peter, additional, Patel, Jyoti D., additional, Mohindra, Nisha Anjali, additional, Carlisle, Jennifer W, additional, Sands, Jacob, additional, He, Zhicong, additional, Winkler, Robert, additional, Liang, Zhiyan, additional, Hammock, Vakessa, additional, Bombelli, Riccardo, additional, Lu, Ming, additional, Xu, Yang, additional, Fu, Tommy, additional, Wang, Cunlin, additional, Yang, Dajun, additional, and Zhai, Yifan, additional

Published
2021
Full Text
View/download PDF

37. Efficacy and safety of immune checkpoint blockade in self‐identified Black patients with advanced non–small cell lung cancer

Author

Nazha, Bassel, primary, Goyal, Subir, additional, Chen, Zhengjia, additional, Engelhart, Anne, additional, Carlisle, Jennifer Wilkinson, additional, Beardslee, Tyler J., additional, Gill, Harpaul, additional, Odikadze, Levani, additional, Liu, Yuan, additional, Mishra, Manoj K., additional, Ramalingam, Suresh S., additional, and Owonikoko, Taofeek Kunle, additional

Published
2020
Full Text
View/download PDF

40. High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.

Author

Piper-Vallillo, Andrew, primary, Rotow, Julia K, additional, Aredo, Jacqueline V, additional, Shaverdashvili, Khvaramza, additional, Luo, Jia, additional, Carlisle, Jennifer W, additional, Husain, Hatim, additional, Muzikansky, Alona, additional, Heist, Rebecca Suk, additional, Rangachari, Deepa, additional, Ramalingam, Suresh S., additional, Wakelee, Heather A., additional, Yu, Helena Alexandra, additional, Sequist, Lecia V., additional, Bauml, Joshua, additional, Neal, Joel W., additional, and Piotrowska, Zofia, additional

Published
2020
Full Text
View/download PDF

41. KRAS G12C mutation associated outcomes among patients with locally advanced non-small cell lung cancer.

Author

Qian, David, primary, Behera, Madhusmita, additional, Steuer, Conor Ernst, additional, Pakkala, Suchita, additional, Carlisle, Jennifer W, additional, Owonikoko, Taofeek Kunle, additional, Fischer-Valuck, Benjamin Walker, additional, Kesarwala, Aparna Hemant, additional, Bradley, Jeffrey, additional, Curran, Walter J, additional, Ramalingam, Suresh S., additional, and Higgins, Kristin Ann, additional

Published
2020
Full Text
View/download PDF

42. YAP1 positive small-cell lung cancer subtype is associated with the T-cell inflamed gene expression profile and confers good prognosis and long term survival.

Author

Owonikoko, Taofeek Kunle, primary, Dwivedi, Bhakti, additional, Chen, Zhengjia, additional, Zhang, Chao, additional, Barwick, Benjamin, additional, Gilbert-Ross, Melissa, additional, Ernani, Vinicius, additional, Zhang, Guojing, additional, Carlisle, Jennifer W, additional, Khuri, Fadlo Raja, additional, Curran, Walter J, additional, Lonial, Sagar, additional, Ramalingam, Suresh S., additional, Sun, Shi-Yong, additional, Waller, Edmund K., additional, and Sica, Gabriel, additional

Published
2020
Full Text
View/download PDF

46. Evaluating the role of race in outcome of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitor (ICI): Our institutional experience.

Author

Nazha, Bassel, primary, Chen, Zhengjia, additional, Goyal, Subir, additional, Engelhart, Anne, additional, Carlisle, Jennifer Wilkinson, additional, Beardslee, Tyler, additional, Gill, Harpaul, additional, Odikadze, Levani, additional, Liu, Yuan, additional, Mishra, Manoj K., additional, Behera, Madhusmita, additional, Ramalingam, Suresh S., additional, and Owonikoko, Taofeek Kunle, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results